Bristol Orencia review extension
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's revised user fee date for Bristol-Myers Squibb's rheumatoid arthritis biologic Orencia (abatacept) is Dec. 29, Bristol says Sept. 6 after the Arthritis Drugs Advisory Committee's unanimous recommendation for approval. The 90-day extension of the original Oct. 1 action date for the T-cell costimulation modulator was "due to the complexity of the chemistry and manufacturing controls section of the application," BMS says, adding that it plans to file an sBLA for a second Orencia manufacturing facility "at the earliest possible date following BLA approval." Bristol appears to be setting the stage to differentiate Orencia from the RA-approved tumor necrosis factor inhibitors (Humira, Enbrel and Remicade). During the advisory committee meeting, the firm suggested that abatacept interferes earlier than the TNF agents in RA pathogenesis and as a result may have a broader mechanism of action...
You may also be interested in...
Bristol Orencia launch
Bristol-Myers Squibb plans to launch its rheumatoid arthritis biologic Orencia (abatacept) in early 2006, the firm says during its third-quarter earnings call Oct. 28. The company expects approval "soon"; FDA extended its Oct. 1 user fee date by 90 days due to complex chemistry, manufacturing and controls sections of the BLA (1Pharmaceutical Approvals Monthly September 2005, In Brief). A full-scale launch will not be possible until FDA approves a third-party manufacturing facility; BMS plans to file an sBLA for the facility post-approval. FDA's Arthritis Drugs Advisory Committee unanimously recommended the first-in-class T-cell co-stimulation modulator for approval Sept. 6...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.